During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Rajat Bannerji, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked, Is odronextamab a feasible option for patients with NHL who are refractory to CAR T-cell therapy?